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1. Introduction 
Abnormal uterine peri- and postmenopausal bleeding represent more than two thirds of the 
Gynecological consultations and the primary exclusion target off such presentations would 
be endometrial cancer.(1)Endometrial cancer is the most common malignancy of the female 
genital tract in the world and the seventh most common cause of death from cancer in 
women in western Europe.(2)The disease thus motivates the development of adequate 
prognostic determinants for more accurate triage of patients through various treatment 
modalities and to provide better insight into the cell biology of the disease.In recent years, 
certain factors have led to an increasing awareness of and emphasis on diagnosis and 
treatment of endometrial cancer. These factors include the declining incidence of cervical 
cancer and related deaths in the United States, prolonged life expectancy, postmenopausal 
use of hormone replacement therapy, and earlier diagnosis. Moreover, the availability of 
easily applied diagnostic tools and a clearer understanding of premalignant lesions of the 
endometrium have led to an increase in the number of women diagnosed with endometrial 
cancer.(3)Screening for the disease and thus its prediction is highly recommended, however , 
there is overlap between the terms prediction and forecast, as prediction implies that some 
outcome is expected, while a forecast may cover a range of possible outcomes.(4) 
2. Risk factors
(5) 
- Associated with increased risk: 
Obesity, Menopausal estrogen use, Diabetes mellitus, Nulliparity, Hypertension, Late 
menopause, Early menarche (<12 yrs), Polycystic ovarian syndrome, and Gall bladder 
disease. 
- Associated with decreased risk: Smoking & Oral contraceptives 
3. Presentation 
Most cases of endometrial cancer are diagnosed in early stages because of abnormal uterine 
bleeding as the presenting symptom in 90% of the cases. (6) It is still debatable, which 
diagnostic tool is best performing for patients with postmenopausal bleeding. Hysteroscopy 
and/or hysteroscopic guided endometrial biopsies as well as endometrial sampling tools 
almost exclusively replaced the older modalities for investigating such cancer such as 
dilatation and curettage (D&C).(7) 
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The Pap test helped somehow in the past through incidental detection of some early cases with 
endometrial cancer, however, the test was proven to be of too low sensitivity and positive 
predictive value in terms of detecting both cervical and endometrial cancers.(8)It must be 
remembered that screening refers to the evaluation of the asymptomatic patient. When 
bleeding occurs, evaluation becomes diagnostic rather than screening. A history of bleeding or 
demonstrated radiographic evidence of endometrial pathology removes a patient from the 
realm of screening and demands investigation, i.e., an endometrial biopsy.(9) 
While screening for endometrial cancer has been evaluated in prospective studies, the 
efficacy of endometrial screening has never been evaluated in a large prospective 
randomized controlled trial.Endometrial biopsy is easily performed as an office procedure 
and has good sensitivity, with the small number of false negatives most likely a result of 
sampling error. Transvaginal ultrasound (TVU) has also been used as a noninvasive 
screening test to evaluate the endometrium.(9) 
4. Diagnosis 
4.1. Screening of asymptomatic cases for early detection 
High index of suspicion must be maintained if endometrial carcinoma will be diagnosed at 
an early stage. Postmenopausal bleeding should be taken to mean endometrial carcinoma 
until proved otherwise.(10) 
1. Transvaginal sonography (TVS): is used to assess the endometrial thickness. This has 
been used as screening method combined with outpatient suction endometrial 
sampling (e.g. using a pipette). The cutoff thickness (myometrium to myometrium) 
expected in postmenopausal women, was once thought to be up to 8 mm.(11) If the 
endometrium is thickened or insufficient material is obtained by biopsy for diagnosis, 
then a more invasive procedure is required. This ideally comprises hysteroscopy 
accompanied or followed by a diagnostic curettage.(11)However, as yet, there is no 
agreed-upon criterion for endometrial thickness that has both a high sensitivity and 
specificity; a high rate of false-positive results is also a limiting factor.(12) 
Previous meta-analyses on endometrial thickness measurement probably have 
overestimated its diagnostic accuracy in the detection of endometrial carcinoma. We advise 
the use of cutoff level of 3 mm for exclusion of endometrial carcinoma in women with 
postmenopausal bleeding.(13) 
TVS has the added advantage of detecting any ovarian lesion and assessing the extent of 
myometrial involvement of endometrial cancer which can be achieved as efficient as 
Magnetic resonance imaging (MRI) utilization for the same purpose.(14) 
2. Progesterone challenge test (PCT): 
It is a reliable, non-invasive test to determine if estrogens, either endogenous or exogenous, 
are present in sufficient quantity to cause endometrial proliferation. Postmenopausal 
women with intact uterus should be given 100 milligrams of progesterone intramuscularly, 
if withdrawal bleeding follows, this indicates high endogenous estrogen priming the 
endometrium denoting a high risk patient. On the other hand, negative PCT i.e. no 
withdrawal bleeding, indicates low endogenous estrogen and consequently low risk patient. 
The test should be repeated on annual basis for those patients. (15) 
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3. Endometrial sampling: 
Cytological study: to detect exfoliated malignant endometrial cells by a cervicovaginal smear 
or jet lavage aspiration. It, unfortunately, gives less reliable results than expected with a 
sensitivity of not more than 50%. (16) 
Endometrial tissue biopsy: Accepted as a first step in evaluating a high-risk patient for 
endometrial carcinoma, with a diagnostic accuracy of 90 – 98%. 
The endometrial tissue biopsy can be obtained using: 
- Vacuum aspiration: using Carman’s cannula which is 3-4mm diameter suction curette 
with 300-600 mm Hg negative pressure. 
- Intrauterine brushing: using a metallic wire with nylon bristles rotated all over the 
uterine cavity. 
- Novak or Randall curette: office procedure, without anesthesia, where scrapes are taken 
from each uterine wall and sent for histopathological examination.(17) 
4.2. Diagnosis of symptomatic cases with postmenopausal uterine bleeding 
Diagnostic curettage has been the standard means for the diagnosis of endometrial pathology. 
The naked-eye picture can be suggestive of malignancy if the curettings are profuse, in the 
form of cheesy lumps rather than strips and if they are dark in color. Failure of the uterine 
wall to "grate" with curetting is suggestive. However, histopathological confirmation should 
be-awaited.(18) 
Fractional curettage (samples taken from the endocervix then from the endometrial cavity) can 
also be used to diagnose or exclude cervical involvement and thus for clinical staging. (19) 
Hysteroscopy can be used in the diagnosis of endometrial carcinoma. Because 15-20% of the 
uterine cavity with possible malignant growth could be missed in conventional curettage, 
hysetroscope allows inspecting the endometrial cavity and indicating the site from which 
endometrial biopsy is to be taken under vision.(20) 
4.3. Genetic analysis 
Genetic testing for mutations in the mismatch repair genes is available, and if a pathogenic 
change is found within a family, predictive testing becomes available for unaffected family 
members to assess microsatellite instability, a feature of mismatch repair genes mutation.(21) 
On the other hand, immunohistochemical staining for p53 gene demonstrating 
overexpression of p53.(22) 
Final diagnosis for pretreatment assessment and staging must entail: 
Radiological imaging: 
- Computer axial tomography (CT) scan with contrast can be helpful in pretreatment 
staging by identifying the depth of myometrial invasion, abdominal lymph node 
involvement, spread to pelvic and extra-pelvic organs, and ureteric invasion. (23) 
- Magnetic resonance imaging (MRI) is a more advanced diagnostic tool in pretreatment 
staging with more accuracy and can detect much smaller tumor deposits and early 
cervical involvement.(24) 
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- Intravenous urography (IVU) to check for ureteric involvement. 
- Plain X-ray chest to detect lung secondaries in advanced stage of the disease. 
- Radioisotope scan to detect distant metastasis and bone deposits. 
- Lymphangiography: for lymph node involvement for preoperative staging; it is now, 
however, replaced by CT scan.(18) 
- Endoscopy: (in advanced cases) 
- Cystoscopy: to detect bladder infiltration. 
- Sigmoidoscopy: to check for rectal and sigmoid colon infiltration.(18) 
4.4. Biochemical markers related to endometrial carcinoma: 
Gynecologists happen to experience that patients with tumors that are identical in grade and 
stage often have significantly different clinical outcomes or responses to therapy. In order to 
identify an objective biological factor correlating with tumor aggressiveness, many tumor 
markers have been investigated. So far, CA125 is one of the most reliable tumor marker for 
adenocarcinoma of the uterus and frequently used in a clinical setting. Elevated CA-125 
levels have also been observed in serum, menstrual effluent, and the peritoneal fluid of 
women with endometrial carcinoma.(25)It can be assumed that if a patient with endometrial 
cancer had an elevated preoperative CA 125, it would probably be a cancer with poor 
prognosis. Thus, CA 125 is considered a positive marker in these cases and its high 
production is associated with increased metastatic potential. In addition, CA 125 levels were 
found to be independent risk factor for pelvic lymph node metastasis.(26, 27) 
Not only in the sera of patients with endometrial carcinoma, do CA 125 levels  
rise significantly, but also in their tissues. Cancer tissues contain CA 125 and the percentage 
of positive CA 125 tissue staining is significantly higher than that of elevated CA 125  
serum levels. An increase in serum CA125 after operation predicted the possibility of 
recurrence. (28, 29) 
The potent cytokine; tumor necrosis factor alpha (TNF-α) was first identified to be 
synthesized and secreted by the human endometrium. The endometrial epithelial cells are a 
major source of TNF-α. TNF-α may be useful in the discrimination of malignant from 
benign gynecological diseases and in monitoring tumor activity in patients early in the 
malignancy process. (30, 31, 32) 
Tumor necrosis factor alpha (TNF α) concentration was determined by a solid phase 
immunoradiometric assay. The rate of abnormally high values of serum TNF α increased 
with advancing stage of the disease. On the other hand, serum TNF α level in cases of 
endometrial hyperplasia was significantly lower than in healthy individuals. It seems that 
the rise of serum TNF α in cases of endometrial carcinoma represents a possible mechanism 
of immune surveillance. It is thus suggested that serum TNF α estimations for the 
differential diagnosis of benign and malignant lesions of the endometrium in women with 
postmenopausal bleeding could be beneficial. (33) 
4.5. Prognostic factors
(19)
 
Multiple factors have been identified which significantly influence the prognosis in 
endometrial carcinoma; some of these factors are interdependent: 
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Prognostic factors in endometrial carcinoma: 
1. Age and body morphology. 
2. Stage. 
3. Histopathologic type. 
4. Histologic differentiation. 
5. Depth of myometrial invasion. 
6. Lymph node involvement. 
7. Peritoneal cytology. 
8. Steroid receptor status 
9. DNA ploidy. 
10. Molecular indices. 
1. Age and body morphology: 
Older patients do worse. Obese patients do better than lean ones. It seems that the obese, 
hyperlipidemic women, with evidence of unopposed estrogen exposure like anovulatory 
uterine bleeding, infertility, late menopause, and hyperplasia of ovarian stroma tend to have 
more differentiated endometrial carcinoma with better prognosis. 
2. Stage: 
Involvement of the cervix definitely worsens the prognosis; cervical stromal invasion  
is worse than involvement of the endocervix only. The overall survival rate for  
endometrial cancer is high as there is a preponderance of women diagnosed with stage I 
disease. 
3. Histological type: 
The rare tumor types of endometrial carcinoma like serous papillary, clear cell and 
squamous carcinoma have a definitely poorer prognosis than usual enometrioid 
adenocarcinoma. The frequent presence of squamous metaplasia not showing malignant 
feature i.e. adenoacanthoma, does not change the prognosis. 
4. Histological differentiation: Tumor grade: 
As the tumor gets less differentiated, the risk of deep myometrial invasion increases. Within 
each stage the prognosis is therefore, influenced by the tumor grade. 
5. Depth of myometrial invasion: 
Deep invasion is associated with higher rates of lymph node involvement and is usually 
associated with lesser degrees of differentiation. Reaching the serosa will shift the disease to 
stage III and is associated with poor prognosis. 
6. Lymph node involvement: 
There is a good deal of correlation between lymph node involvement and other prognostic 
factors. In stage I disease, the incidence of pelvic lymph node involvement is about 10 % and 
the 5-years survival in these subset is only 30% as compared with more than 70% for the 
whole of stage I cases. (34) 
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7. Peritoneal cytology: 
Obtaining peritoneal washings for cytology examination is an easy procedure for 
assessment of prognosis. However, its value independent of other prognostic indicators is 
not fully established. (35) 
8. Hormone (steroid) receptor status:  
Estrogen receptor and progesterone receptor levels have been shown to be prognostic 
indicators for endometrial cancers independent of grade. Patients with tumors positive for 
one or both receptors have longer survival than patients whose carcinomas lack the 
corresponding receptors. Even patients with metastasis have an improved prognosis with 
receptor positive tumors. Progesterone receptor levels appear to be stronger predictors of 
survival than estrogen receptor levels, and the higher the absolute level of the receptor, the 
better the prognosis. (36) 
9. DNA ploidy and proliferative index: 
Flow cytometry has been used in assessment of the ploidy of the tumor. This determines 
cellular nuclear DNA content and measures the fraction of the tumor cells in proliferative 
phase (S- phase). Flow cytometry will determine DNA histogram, which reflects the cell 
cycle phase. G0 and G1 cells contain diploid nuclear DNA content. In a well-differentiated 
tumor, a smaller number of cells enter the S-phase and begin DNA replication (S-phase 
fraction). DNA ploidy can be denoted as DNA index (DI), which is the numerical ratio of 
DNA content of the tumor cells to the DNA content of G0/G1 peak of normal control 
population. A diploid tumor has a DI range of 0.95 % to 1.1 and a tetraploid tumor has a DI 
range of 1.9 to 2%; peaks outside these ranges e.g. 1.5 or 2.6 are defined as aneuploid. Most 
endometrial cancers are diploid but aneuploidy indicates advanced disease and a poor 
prognosis. A raised fraction of cells in the S-phase (with DI around 2) also indicates a poor 
prognosis. 
10. Genetic and molecular markers: 
Analysis of the mutations in mismatch repair (MMR) genes can be achieved through 
studying blood samples or tumor blocks to assess microsatellite instability, a feature of 
mismatch repair gene mutations. These mutations have been reported in 10% to 20% of 
endometrial adenocarcinomas. Alteration of the tumor suppressor gene p53 has also been 
demonstrated in about 20% of endometrial carcinomas and has been associated with 
papillary serous cell type, advanced stage and poor prognosis. (37,38) 
In summary, endometrial cancer screening, and thus its outcome prediction (forecast) seem 
to be achievable in a more variety of ways than any other female genital malignancy. Early 
detection is definitely the first step to attain a complete cure. The management options for 
endometrial cancer, and thus the survival rate from the disease would depend largely on 
early detection modalities mentioned above. The following are some recommendations from 
the American cancer Society (ACS) for early detection of the disease based on patients' 
characteristics.(9)Recommendations for Women at Average Risk: There is no indication that 
screening for endometrial cancer is warranted for women who have no identified risk 
factors.(39) 
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Recommendations for Women at Increased Risk: There is no indication that screening for 
endometrial cancer should be recommended for women at increased risk for endometrial 
cancer because of history of unopposed estrogen therapy, late menopause, tamoxifen 
therapy, nulliparity, infertility or failure to ovulate, obesity, diabetes, or hypertension.(39) 
Recommendations for Women at High Risk: The American Cancer Society recommends that 
annual screening for endometrial cancer with endometrial biopsy should be offered by age 
35 for women with or at risk for hereditary nonpolyposis colorectal cancer (HNPCC). 
Women in this high-risk group should be informed about the risks and symptoms of 
endometrial cancer, and should be informed about potential benefits, risks, and limitations 
of testing for early endometrial cancer detection. 
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